Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A decade of clinical development of PARP inhibitors in perspective.
Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. Mateo J, et al. Among authors: kaye sb. Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192. Ann Oncol. 2019. PMID: 31218365 Free PMC article. Review.
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Sandhu SK, et al. Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. Ann Oncol. 2013. PMID: 23524863 Free article. Clinical Trial. No abstract available.
Revisiting the role of antiandrogen strategies in ovarian cancer.
Papadatos-Pastos D, Dedes KJ, de Bono JS, Kaye SB. Papadatos-Pastos D, et al. Among authors: kaye sb. Oncologist. 2011;16(10):1413-21. doi: 10.1634/theoncologist.2011-0164. Epub 2011 Sep 23. Oncologist. 2011. PMID: 21948654 Free PMC article. Review.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR. Mateo J, et al. Among authors: kaye sb. Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8. Target Oncol. 2016. PMID: 27169564 Free article. Clinical Trial.
Reversing resistance to targeted therapy.
Vidal L, Attard G, Kaye S, De Bono J. Vidal L, et al. J Chemother. 2004 Nov;16 Suppl 4:7-12. doi: 10.1179/joc.2004.16.Supplement-1.7. J Chemother. 2004. PMID: 15688600 Review.
735 results